TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28961996

Group type: EXPERIMENTAL
Intervention: Amoxicillin-containing regimens
Number of subjects: 2339

Group type: EXPERIMENTAL
Intervention: Clarithromycin triple therapy
Number of subjects: 2339

Group type: EXPERIMENTAL
Intervention: Breakpoint of amoxicillin resistance ≥0.125 mg/L
Number of subjects: 2339
Study: 26272173

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin detemir
Number of subjects: 12

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 12
Study: 23292848

Group type: EXPERIMENTAL
Intervention: Eccentric resistance training (ECC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Concentric resistance training (CON)
Number of subjects: 34
Study: 20501520

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Remifentanil (0.3 μg/kg/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (Dexmedetomidine and Remifentanil)
Number of subjects: 0
Study: 18327852

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACEI therapy
Number of subjects: 0
Study: 17144553

Group type: EXPERIMENTAL
Intervention: Muscular contrapulsation (MCP) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Muscular contrapulsation (MCP) in combination with balneotherapy (radon and iodine-bromine baths)
Number of subjects: 0
Study: 14658990

Group type: EXPERIMENTAL
Intervention: Systematic approach to treatment including patient education, encouragement of exposure, attention to relevant comorbidities, use of empirically proven pharmacotherapies, and psychosocial interventions of adequate intensity and duration.
Number of subjects: 0
Study: 10718785

Group type: EXPERIMENTAL
Intervention: Azimilide dihydrochloride in the fed state (high-fat meal)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Azimilide dihydrochloride in the fasted state
Number of subjects: 30
Study: 8736458

Group type: EXPERIMENTAL
Intervention: Indomethacin treatment for 1 month
Number of subjects: 41
Study: 1550474

Group type: EXPERIMENTAL
Intervention: Liquid oral intake 4 hours after removal of the tube
Number of subjects: 171

Group type: COMPARATOR
Intervention: Ordinary solid intake soon after nasogastric tube removal
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 171
Study: 3875296

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg bwxh nimodipine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg bwxh nimodipine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Higher dosages of nimodipine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (0.9% NaCl as placebo)
Number of subjects: 64
Study: 31502749

Group type: EXPERIMENTAL
Intervention: gemigliptin 50 mg
Number of subjects: 71

Group type: COMPARATOR
Intervention: dapagliflozin 10 mg
Number of subjects: 71

Group type: COMPARATOR
Intervention: gemigliptin 50 mg and dapagliflozin 10 mg
Number of subjects: 71
Study: 30314512

Group type: EXPERIMENTAL
Intervention: Early eye movement desensitization and reprocessing (EMDR) intervention performed by a trained psychologist during ER stay
Number of subjects: 446

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Early eye movement desensitization and reprocessing (EMDR) intervention
Number of subjects: 446
Study: 27018153

Group type: EXPERIMENTAL
Intervention: Endobronchial allergen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE)
Number of subjects: 18
Study: 24607365

Group type: EXPERIMENTAL
Intervention: Abstinence, Methadone & Work Reinforcement
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Methadone & Work Reinforcement
Number of subjects: 98

Group type: COMPARATOR
Intervention: Work Reinforcement
Number of subjects: 98
Study: 22491353

Group type: EXPERIMENTAL
Intervention: Oral alpha‐methyl‐para‐tyrosine (AMPT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham depletion (diphenhydramine)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CD-induced anhedonic symptoms
Number of subjects: 19
Study: 20410913

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 or 3 g day(‐1) plus oral corticosteroids
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo plus oral corticosteroids
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 96
Study: 18848429

Group type: EXPERIMENTAL
Intervention: 3D‐MTEE imaging of prosthetic MVs and annuloplasty rings
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 3D‐MTEE imaging
Number of subjects: 87
Study: 15823285

Group type: EXPERIMENTAL
Intervention: orlistat 120 mg plus a moderate-fat meal (MFO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: orlistat 120 mg plus a high-fat meal (HFO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo plus a high-fat meal (HFP)
Number of subjects: 10
Study: 12433452

Group type: EXPERIMENTAL
Intervention: Salbutamol dry powder formulations (50 microg to 400 microg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MSLI or ACI impactors for in vitro testing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Equivalence testing criteria
Number of subjects: 12
Study: 10526025

Group type: EXPERIMENTAL
Intervention: Two-stage management (Group A): Preoperative endoscopic retrograde cholangiography (ERC) with endoscopic stone extraction (ESE) followed by laparoscopic cholecystectomy (LC) during the same hospital admission.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Single-stage laparoscopic management (Group B): Single-stage laparoscopic treatment.
Number of subjects: 300
Study: 8719512

Group type: EXPERIMENTAL
Intervention: DTaP vaccine (acellular pertussis vaccine containing pertussis toxoid, filamentous hemagglutinin, and pertactin)
Number of subjects: 557

Group type: COMPARATOR
Intervention: DTP-Connaught (whole-cell pertussis vaccine)
Number of subjects: 557

Group type: COMPARATOR
Intervention: DTP-Lederle (whole-cell pertussis vaccine)
Number of subjects: 557
Study: 2200826

Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg once weekly
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6117309

Group type: EXPERIMENTAL
Intervention: Prizidilol hydrochloride 400 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Propranolol 40 mg + Hydralazine 25 mg or 50 mg
Number of subjects: 8
Study: 30973344

Group type: EXPERIMENTAL
Intervention: Internet-delivered computerized cognitive behavioral therapy (ICBT) plus usual care (UC)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ICBT plus UC
Number of subjects: 23
Study: 29152825

Group type: EXPERIMENTAL
Intervention: FBT + CRT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FBT + AT
Number of subjects: 30

Group type: COMPARATOR
Intervention: FBT
Number of subjects: 30
Study: 26945478

Group type: EXPERIMENTAL
Intervention: Brief mindfulness instructions
Number of subjects: 319

Group type: COMPARATOR
Intervention: Distraction control instructions
Number of subjects: 319

Group type: COMPARATOR
Intervention: No-instruction control conditions
Number of subjects: 319
Study: 24766337

Group type: EXPERIMENTAL
Intervention: Strongyloides stercoralis infection
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (patients without S. stercoralis larvae)
Number of subjects: 149
Study: 22126282

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus systemic amoxicillin (500 mg) and metronidazole (400 mg) 3 times a day for 14 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 24
Study: 20881664

Group type: EXPERIMENTAL
Intervention: Aerosolized nebulization of amphotericin B lipid complex at 1 mg/kg every 24 hr for 4 days
Number of subjects: 35
Study: 18981770

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir [400/100 mg twice a day (LPV/r)]
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir [500/200 mg twice a day (TPV/r200)]
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir [500/100 mg twice a day (TPV/r100)]
Number of subjects: 140
Study: 15799981

Group type: EXPERIMENTAL
Intervention: Consumer-directed voucher
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Combination of nurse intervention and consumer-directed voucher
Number of subjects: 1394

Group type: COMPARATOR
Intervention: Disease-management-health-promotion nurse intervention
Number of subjects: 1394
Study: 12750967

Group type: EXPERIMENTAL
Intervention: Scotchbond 1 + Filtek Flow
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scotchbond 1 + F2000
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop + experimental flowable composite
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (deionized water)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Compomer restorations
Number of subjects: 0
Study: 10364993

Group type: EXPERIMENTAL
Intervention: Propofol 20 mg i.v. every 30 s to a maximum of 5 mg kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thiopental 25 mg i.v. every 30 s
Number of subjects: 20
Study: 8896392

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF at doses of 0.3 and 1.0 microgram/kg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF
Number of subjects: 0
Study: 2071885

Group type: EXPERIMENTAL
Intervention: Amitriptyline (clinically effective doses)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Tranylcypromine (single treatment)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Amitriptyline and Tranylcypromine (combination treatment)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (none specified)
Number of subjects: 53
Study: 6402091

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 45
Study: 30161086

Group type: EXPERIMENTAL
Intervention: 4.0% Menthol (M)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Placebo (P)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 47
Study: 30691396

Group type: EXPERIMENTAL
Intervention: Live attenuated varicella-zoster vaccine
Number of subjects: 1500
Study: 27353247

Group type: EXPERIMENTAL
Intervention: Supplementary arm and upper body exercise programme
Number of subjects: 70
Study: 25923580

Group type: EXPERIMENTAL
Intervention: CHO mouth‐rinse (6.4% maltodextrin)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 9
Study: 24667460

Group type: EXPERIMENTAL
Intervention: Nasal glucagon-like peptide-1 (GLP-1) 1.2 mg administered before every meal for 2 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22971530

Group type: EXPERIMENTAL
Intervention: Bisphosphonates (clodronate therapy group)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Simple chemotherapy (control group)
Number of subjects: 53
Study: 19397644

Group type: EXPERIMENTAL
Intervention: Bioresorbable membrane (MC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Periosteum (PC)
Number of subjects: 14
Study: 18086048

Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (CaHA)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Human-based collagen
Number of subjects: 117
Study: 15057674

Group type: EXPERIMENTAL
Intervention: Humalog Mix50 injected three times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Premixed human insulin 30/70 injected twice daily
Number of subjects: 40
Study: 10807752

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 867

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 867
Study: 8623866

Group type: EXPERIMENTAL
Intervention: Fish oil (1080 mg icosapentaenoic acid, 720 mg docosahexaenoic acid, and 1.5 mg vitamin E) daily for 2 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo for the first 2 months
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fish oil for 2 months after placebo
Number of subjects: 42
Study: 1535329

Group type: EXPERIMENTAL
Intervention: Didemnin B at 2.6 mg/m2 iv every 28 days
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Didemnin B at 5.6 mg/m2 iv every 28 days
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Trimetrexate at 12 mg/m2/day iv for 5 days, repeated every 21 days
Number of subjects: 43
Study: 6419679

Group type: EXPERIMENTAL
Intervention: Oral lysine hydrochloride therapy (400 mg, three times a day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30553130

Group type: EXPERIMENTAL
Intervention: Home monitoring with IT-supported specialist management
Number of subjects: 202

Group type: COMPARATOR
Intervention: Home monitoring alone
Number of subjects: 202
Study: 30815169

Group type: EXPERIMENTAL
Intervention: Acute care patient portal
Number of subjects: 63
Study: 25968166

Group type: EXPERIMENTAL
Intervention: QS Alex laser
Number of subjects: 17

Group type: COMPARATOR
Intervention: QS Nd:YAG laser
Number of subjects: 17
Study: 22920815

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) in patients with CHF
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) in patients with SH
Number of subjects: 146

Group type: COMPARATOR
Intervention: Continuous glucose monitoring (CGM) in outpatients
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) during hypoglycemia
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) during euglycemia
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) during hyperglycemia
Number of subjects: 146
Study: 20868803

Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1156
Study: 18293124

Group type: EXPERIMENTAL
Intervention: 3-day instrument
Number of subjects: 134

Group type: COMPARATOR
Intervention: 7-day instrument
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Participants reporting 100% adherence at more than half of study visits
Number of subjects: 134
Study: 16181527

Group type: EXPERIMENTAL
Intervention: Conventional acupuncture plus needling in DU20
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conventional acupuncture plus needling in HT7
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conventional acupuncture plus needling in DU26
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination of DU20, DU26, and HT7
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional acupuncture for hemiplegia
Number of subjects: 50
Study: 14625515

Group type: EXPERIMENTAL
Intervention: Professional golfers (PR)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Collegiate golfers (CO)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: General amateur golfers (AM)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Collegiate recreational golfers (RE)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Non-golfing college students (CG)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Senior population of non-golfers (SC)
Number of subjects: 128
Study: 10782483

Group type: EXPERIMENTAL
Intervention: Propolis ointment applied four times daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acyclovir ointment applied four times daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo ointment applied four times daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propolis ointment
Number of subjects: 90
Study: 8781676

Group type: EXPERIMENTAL
Intervention: Hydrolyzed, ultrafiltered cow's milk whey formula (Profylac), n = 32
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ordinary cow's milk formula, n = 39
Number of subjects: 91

Group type: COMPARATOR
Intervention: Breast-fed exclusively for more than 9 months, n = 20 (control group)
Number of subjects: 91
Study: 1355880

Group type: EXPERIMENTAL
Intervention: Hypervolemic haemodilution for 2 hours (Group A)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Hypervolemic haemodilution for 4 hours (Group B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Hypervolemic haemodilution for 6 hours (Group C)
Number of subjects: 75
Study: 4074444

Group type: EXPERIMENTAL
Intervention: 200 mg AQ‐A 39 intravenously
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control/Placebo
Number of subjects: 6
Study: 31503423

Group type: EXPERIMENTAL
Intervention: Extremely randomized tree learning models
Number of subjects: 0
Study: 29190155

Group type: EXPERIMENTAL
Intervention: PC-18 at 37.5 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PC-18 at 7.5 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PC-18 at 12.5 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27475046

Group type: EXPERIMENTAL
Intervention: Ketone ester-based nutrition
Number of subjects: 39
Study: 24462244

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) sessions coded using the motivational interviewing skill code 2.5
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) sessions
Number of subjects: 170
Study: 22894938

Group type: EXPERIMENTAL
Intervention: Race-relevant Implicit Association Test (IAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Race-irrelevant Implicit Association Test (IAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Explicit prejudice measure
Number of subjects: 0

Group type: COMPARATOR
Intervention: White interaction partner
Number of subjects: 0
Study: 20645521

Group type: EXPERIMENTAL
Intervention: Azelaic acid gel 15% plus doxycycline 40 mg once daily
Number of subjects: 207

Group type: COMPARATOR
Intervention: Metronidazole gel 1% plus doxycycline 40 mg once daily
Number of subjects: 207
Study: 17988756

Group type: EXPERIMENTAL
Intervention: Short messaging service (SMS) and Internet intervention for 12 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study: 19137909

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of famotidine with calcium carbonate and magnesium hydroxide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Common formulation of famotidine
Number of subjects: 12
Study: 15016779

Group type: EXPERIMENTAL
Intervention: Highly purified urinary FSH (u-hFSH)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Recombinant human FSH (r-hFSH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (normally menstruating women)
Number of subjects: 50
Study: 12539560

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 76
Study: 9374884

Group type: EXPERIMENTAL
Intervention: Nutrition improvement project based on home garden production and nutrition education
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control commune (Ching Cong)
Number of subjects: 720
Study: 8339853

Group type: EXPERIMENTAL
Intervention: Sulodexide administration during hyperglycaemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Induced hyperglycaemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Type 1 diabetic patients (basal state)
Number of subjects: 0
Study: 3756378

Group type: EXPERIMENTAL
Intervention: Post-meal condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noise exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low levels of trait or state anxiety
Number of subjects: 0
Study: 11791960

Group type: EXPERIMENTAL
Intervention: Myrrh at a dose of 10 mg/kg of body weight/day for three days
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Myrrh at a dose of 10 mg/kg of body weight/day for six days (re-treatment)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Biopsy specimens six months after treatment
Number of subjects: 204
Study: 30975678

Group type: EXPERIMENTAL
Intervention: 6-week, group-based, individualised, patient-centred rehabilitation programme consisting of multimodal exercise, exercise education and health education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (ie, no care)
Number of subjects: 0
Study: 29319209

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone prophylaxis
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Induction therapy with fluoroquinolone prophylaxis
Number of subjects: 230

Group type: COMPARATOR
Intervention: Induction therapy without prophylaxis (DFCI 05-001)
Number of subjects: 230
Study: 27093482

Group type: EXPERIMENTAL
Intervention: Folic acid-containing supplements
Number of subjects: 162

Group type: COMPARATOR
Intervention: Educational text messages (TMs)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (no supplements, no TMs)
Number of subjects: 162

Group type: COMPARATOR
Intervention: TM only
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Supplement only
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: TM + supplement
Number of subjects: 162
Study: 24165197

Group type: EXPERIMENTAL
Intervention: 60 Hz stimulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: 130 Hz stimulation
Number of subjects: 20
Study: 23033992

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure
Number of subjects: 8

Group type: COMPARATOR
Intervention: Filtered air (FA) exposure
Number of subjects: 8
Study: 20961243

Group type: EXPERIMENTAL
Intervention: Transfemoral transcatheter implantation of a balloon-expandable bovine pericardial valve (TAVI)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Standard therapy (including balloon aortic valvuloplasty)
Number of subjects: 358
Study: 18341722

Group type: EXPERIMENTAL
Intervention: Herniography
Number of subjects: 310
Study: 16111538

Group type: EXPERIMENTAL
Intervention: High levels of HOXA9 expression in haemopoietic cells in adults over sixty.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low levels of HOXA9 expression in haemopoietic cells during early adulthood.
Number of subjects: 0
Study: 11881904

Group type: EXPERIMENTAL
Intervention: Intention to produce a spatial consequence in the environment to a spatially neutral stimulus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control experiments
Number of subjects: 0
Study: 10404003

Group type: EXPERIMENTAL
Intervention: Nurse practitioners
Number of subjects: 232

Group type: COMPARATOR
Intervention: Medical officers
Number of subjects: 232